28205317|t|Oxidative stress and immunosenescence in spleen of obese mice can be reversed by 2-hydroxyoleic acid
28205317|a|We aimed to investigate the effects of obesity on oxidative stress and leukocyte function in spleen of mice, and to assess whether supplementation with 2-hydroxyoleic acid (2-OHOA) or n-3 polyunsaturated fatty acids (PUFA) could reverse those effects. Female ICR/CD1 mice (8 weeks old, n = 24) received an obesogenic diet (22% fat for 4 weeks and 60% fat for 14 weeks). After 6 weeks, mice were split in three groups (n = 8/ group): no supplementation, 2-OHOA supplementation (1500 mg kg(-1)) and n-3 PUFA supplementation (EPA + DHA, 3000 mg kg(-1) diet). Eight mice were fed standard diet for the whole duration of the study (control group). At the end of the experiment, the following variables were assessed in spleens: levels of reduced (GSH) and oxidized (GSSG) glutathione, GSH / GSSG, xanthine oxidase (XO) activity, lipid peroxidation, lymphocyte chemotaxis, natural killer (NK) activity and mitogen (ConA and LPS)-induced lymphocyte proliferation. Obese animals presented higher GSSG levels (P = 0.003), GSSG / GSH ratio (P = 0.013), lipid peroxidation (P = 0.004), XO activity (P = 0.015) and lymphocyte chemotaxis (P < 0.001), and lower NK activity (P = 0.003) and proliferation in response to ConA (P < 0.001) than controls. 2-OHOA reversed totally or partially most of the changes (body weight, fat content, GSSG levels, GSH / GSSG, lipid peroxidation, chemotaxis and proliferation, all P < 0.05), while n-3 PUFA reversed the increase in XO activity (P = 0.032). In conclusion, 2-OHOA, and to a lesser extent n-3 PUFA, could ameliorate the oxidative stress and alteration of leukocyte function in spleen of obese mice. Our findings support a link between obesity and immunosenescence and suggest a potential therapeutic tool for obesity -related immune dysfunction. This article is protected by copyright. All rights reserved.
28205317	0	16	Oxidative stress	T049	C0242606
28205317	21	37	immunosenescence	T039	C0596761
28205317	41	47	spleen	T023	C0037993
28205317	51	61	obese mice	T015	C0025933
28205317	81	100	2-hydroxyoleic acid	T109,T121	C1436659
28205317	140	147	obesity	T047	C0028754
28205317	151	167	oxidative stress	T049	C0242606
28205317	172	181	leukocyte	T025	C0023516
28205317	182	190	function	T043	C0007613
28205317	194	200	spleen	T023	C0037993
28205317	204	208	mice	T015	C0025929
28205317	232	247	supplementation	T061	C0242297
28205317	253	272	2-hydroxyoleic acid	T109,T121	C1436659
28205317	274	280	2-OHOA	T109,T121	C1436659
28205317	285	316	n-3 polyunsaturated fatty acids	T109,T121,T123	C0015689
28205317	318	322	PUFA	T109,T121,T123	C0015689
28205317	353	359	Female	T032	C0086287
28205317	360	372	ICR/CD1 mice	T015	C2697641
28205317	376	381	weeks	T079	C0439230
28205317	407	422	obesogenic diet	T168	C0012155
28205317	428	431	fat	T109,T168	C0012171
28205317	438	443	weeks	T079	C0439230
28205317	452	455	fat	T109,T168	C0012171
28205317	463	468	weeks	T079	C0439230
28205317	479	484	weeks	T079	C0439230
28205317	486	490	mice	T015	C0025929
28205317	511	517	groups	UnknownType	C0681860
28205317	526	531	group	UnknownType	C0681860
28205317	534	552	no supplementation	UnknownType	C0681860
28205317	554	576	2-OHOA supplementation	UnknownType	C0681860
28205317	598	622	n-3 PUFA supplementation	UnknownType	C0681860
28205317	624	627	EPA	T109,T121,T123	C0000545
28205317	630	633	DHA	T109,T121	C0556150
28205317	663	667	mice	T015	C0025929
28205317	686	690	diet	T168	C0012155
28205317	705	713	duration	T079	C0449238
28205317	721	726	study	T062	C2603343
28205317	728	741	control group	T096	C0009932
28205317	762	772	experiment	T062	C0681814
28205317	788	797	variables	T080	C0439828
28205317	803	811	assessed	T052	C1516048
28205317	815	822	spleens	T023	C0037993
28205317	824	830	levels	T080	C0441889
28205317	834	841	reduced	T116,T123	C0017817
28205317	843	846	GSH	T116,T123	C0017817
28205317	852	879	oxidized (GSSG) glutathione	T116,T121	C0061516
28205317	881	884	GSH	T116,T123	C0017817
28205317	887	891	GSSG	T116,T121	C0061516
28205317	893	923	xanthine oxidase (XO) activity	T044	C1151293
28205317	925	943	lipid peroxidation	T044	C0023775
28205317	945	966	lymphocyte chemotaxis	T043	C0312862
28205317	968	996	natural killer (NK) activity	T043	C1317556
28205317	1001	1008	mitogen	T121	C0026249
28205317	1010	1014	ConA	T116,T123	C0009630
28205317	1019	1022	LPS	T109	C0023810
28205317	1032	1056	lymphocyte proliferation	T043	C0596873
28205317	1058	1063	Obese	T032	C0424612
28205317	1064	1071	animals	T008	C0003062
28205317	1082	1088	higher	T080	C0205250
28205317	1089	1093	GSSG	T116,T121	C0061516
28205317	1094	1100	levels	T080	C0441889
28205317	1114	1118	GSSG	T116,T121	C0061516
28205317	1121	1124	GSH	T116,T123	C0017817
28205317	1125	1130	ratio	T081	C0456603
28205317	1144	1162	lipid peroxidation	T044	C0023775
28205317	1176	1187	XO activity	T044	C1151293
28205317	1204	1225	lymphocyte chemotaxis	T043	C0312862
28205317	1249	1260	NK activity	T043	C1317556
28205317	1277	1290	proliferation	T169	C1514485
28205317	1306	1310	ConA	T116,T123	C0009630
28205317	1328	1336	controls	T096	C0009932
28205317	1338	1344	2-OHOA	T109,T121	C1436659
28205317	1387	1394	changes	T081	C0443172
28205317	1396	1407	body weight	T032	C0005910
28205317	1422	1426	GSSG	T116,T121	C0061516
28205317	1427	1433	levels	T080	C0441889
28205317	1435	1438	GSH	T116,T123	C0017817
28205317	1441	1445	GSSG	T116,T121	C0061516
28205317	1447	1465	lipid peroxidation	T044	C0023775
28205317	1467	1477	chemotaxis	T043	C0008018
28205317	1482	1495	proliferation	T043	C0596290
28205317	1518	1526	n-3 PUFA	T109,T121,T123	C0015689
28205317	1540	1548	increase	T169	C0442805
28205317	1552	1563	XO activity	T044	C1151293
28205317	1592	1598	2-OHOA	T109,T121	C1436659
28205317	1623	1631	n-3 PUFA	T109,T121,T123	C0015689
28205317	1654	1670	oxidative stress	T049	C0242606
28205317	1675	1685	alteration	T078	C1515926
28205317	1689	1698	leukocyte	T025	C0023516
28205317	1699	1707	function	T043	C0007613
28205317	1711	1717	spleen	T023	C0037993
28205317	1721	1731	obese mice	T015	C0025933
28205317	1737	1745	findings	T033	C0243095
28205317	1769	1776	obesity	T047	C0028754
28205317	1781	1797	immunosenescence	T039	C0596761
28205317	1822	1838	therapeutic tool	T169	C0302350
28205317	1843	1850	obesity	T047	C0028754
28205317	1860	1878	immune dysfunction	T047	C0021053